Skip to main content
SpringerLink
Log in

First generation aromatase inhibitors — aminoglutethimide and testololactone

  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Summary

Aminoglutethimide and testololactone may be considered the first generation aromatase inhibitors for the endocrine treatment of breast carcinoma. Initially, both of these agents were designed and used clinically based on different concepts of their mechanisms of action. Only later were they both demonstrated to inhibit aromatase.

Curiously, testololactone was earlier and more widely used than aminoglutethimide in treating advanced breast carcinoma. The discovery of the peripheral aromatase inhibition as the proper mechanism of action was delayed for both the agents but was relatively more timely for aminoglutethimide. Paradoxically, the clinical use of testololactone has become already obsolete since its true mechanism of action was discovered.

Aminoglutethimide is still the most widely used aromatase inhibitor in treating advanced breast carcinoma. Due to the initial misinterpretation of its mechanism of action, aminoglutethimide was used for a long time at a relative high daily dose, always combined with hydrocortisone. Subsequent phase II and then randomized phase III studies demonstrated an equivalent efficacy using half (500 mg) of the previous conventional daily dose (1000 mg), with hydrocortisone. Very recently, a randomized clinical trial demonstrated that administering this lower dose without hydrocortisone did not significantly decrease the clinical efficacy.

By decreasing the dose of aminoglutethimide, the incidence of side effects has been reduced. So, the last paradoxical aspect of the aminoglutethimide story is that this agent seemed initially very toxic but finally, with the new schedules, shows a very low toxicity profile, especially after the first few weeks of treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Council on Drugs: New drugs and developments in therapeutics. J Am Med Assoc 179:798, 1962

    Google Scholar 

  2. Camacho AM, Brough AJ, Cash R, Wilroy RS: Adrenal toxicity associated with the administration of an anticonvulsant drug. J Pediatr 68:852–853, 1966

    Google Scholar 

  3. Dexter RN, Fishman LM, Ney RC, Liddle GW: Inhibition of adrenal corticosteroid synthesis by aminoglutethimide: Studies on the mechanism of action. J Clin Endocrinol 27:473–480, 1967

    Google Scholar 

  4. Fishman LM, Liddle GW, Island DP, Fleischer N, Kuchel O: Effect of aminoglutethimide on adrenal function in man. J Clin Endocrinol 27:481–490, 1967

    Google Scholar 

  5. Cash R, Brough AJ, Cohen MNP, Sotch PS: Aminoglutethimide (Elipten-Ciba) as an inhibitor of steroidogenesis: Mechanism of action and therapeutic trial. J Clin Endocrinol 17:1239–1248, 1967

    Google Scholar 

  6. Griffiths CT, Hall TC, Saba Z, Barlow JJ, Nevinny HB: Preliminary trial of aminoglutethimide in breast cancer. Cancer 32:31–37, 1973

    Google Scholar 

  7. Lipton A, Santen RJ: Medical adrenalectomy using aminoglutethimide and dexamethasone in advanced breast cancer. Cancer 33:503–512, 1974

    Google Scholar 

  8. Santen RJ, Samojlik E, Lipton A, Harvey H, Ruby EB, Wells SA, Kendall J: Kinetic, hormonal and clinical studies with aminoglutethimide in breast cancer. Cancer 39:2948–2958, 1977

    Google Scholar 

  9. Grodin JM, Siiteri PK, MacDonald PC: Source of estrogen production in postmenopausal women. J Clin Endocrinol Metab 36:207–214, 1973

    Google Scholar 

  10. Thompson EA Jr, Siiteri PK: Utilization of oxygen and reduced nicotinamide adenine dinucleotide phosphate by human placental microsomes during aromatization of androstenedione. J Biol Chem 249:5364–5372, 1974

    Google Scholar 

  11. Thompson EA Jr, Siiteri PK: The involvement of human placental microsomal cytochrome P-450 in aromatization. J Biol Chem 249:5373–5378, 1974

    Google Scholar 

  12. Newsome HH, Brown PW, Terz JJ, Lawrence W Jr: Medical and surgical adrenalectomy in patients with advanced breast carcinoma. Cancer 39:542–546, 1977

    Google Scholar 

  13. Wells SA Jr, Santen RJ, Lipton A, Haagensen DE Jr, Ruby EJ, Harvey H, Dilley WG: Medical adrenalectomy with aminoglutethimide: Clinical studies in postmenopausal patients with metastatic breast carcinoma. Ann Surg 184:475–484, 1978

    Google Scholar 

  14. Murray RML, Pitt P: Medical adrenalectomy in patients with advanced breast cancer resistant to anti-oestrogen treatment. Breast Cancer Res Treat 1:91–95, 1981

    Google Scholar 

  15. Horsley JS, Newsome HH, Brown PW, Neifeld JP, Terz JJ, Lawrence W Jr: Medical adrenalectomy in patients with advanced breast cancer. Cancer 49:1145–1149, 1982

    Google Scholar 

  16. Paridaens R, Heuson JC: Medical adrenalectomy in advanced breast cancer in postmenopausal women. Results and tolerability.In: Paesi FJA (ed) Aminoglutethimide (Orimeten). Mechanism of Action and Clinical Results in Breast Cancer. Ciba Geigy, Basel, 1982, pp 99–110

    Google Scholar 

  17. Graves PE, Salhanick HA: Stereoselective inhibition of aromatase by enantiomers of aminoglutethimide. Endocrinol 105:52–57, 1979

    Google Scholar 

  18. Bonneterre J, Coppens K, Mauriac L, Metz M, Rouesse J, Armand JP, Fargeot P, Mathieu M, Tubiana M, Cappellaere P: Aminoglutethimide in advanced breast cancer: Clinical results of a French multicentric randomized trial comparing 500 mg and 1 g/day. Eur J Cancer Clin Oncol 21:1153–1158, 1985

    Google Scholar 

  19. Illiger HJ, Caffier H, Carterier B, Eggeling B, Hartlapp J, Hartwich G, Katlitz EU, Katz R, Klasen H, Mayr AC, Preiss G, Rieche K, Wellens N: Aminoglutethimide in advanced breast cancer — Low dose vs standard dose [abstract]. J Cancer Res Clin Oncol (D) 3:S69, 1986

    Google Scholar 

  20. Upright C, Ragaz J, Basco V, Grafton C: Double blind randomized trial of conventional versus low dose aminoglutethimide and hydrocortisone in patients with metastatic hormone responsive breast cancer. Proc ASCO 9:45, 1990

    Google Scholar 

  21. Robustelli Della Cuna G: 500 mg versus 1000 mg aminoglutethimide in advanced breast cancer: 3 year results of an Italian multicentric trial. Eur J Cancer 2:569, 1991

    Google Scholar 

  22. Elomaa I, Blomquist C, Rissanen P: Aminoglutethimide as second line therapy in advanced breast cancer. Breast Cancer Res Treat 7:S51-S54, 1986

    Google Scholar 

  23. Harris AL, Powles TJ, Smith IE, Coombes RC, Ford HT, Gazet JC, Harmer CL, Morgan M, White H, Parsons CA, McKinna JA: Aminoglutethimide for the treatment of advanced postmenopausal breast cancer. Eur J Cancer Clin Oncol 49:11–17, 1983

    Google Scholar 

  24. Brodie AMH: Overview of recent development of aromatase inhibitors. Cancer Res 42:3312s-3314s, 1982

    Google Scholar 

  25. Powles TJ: The role of aromatase inhibitors in breast cancer. Semin Oncol 10(Suppl 4):20–24, 1983

    Google Scholar 

  26. Santen RJ: Aminoglutethimide as an aromatase inhibitor in the treatment of cancer. Cancer Treat Rev 11:325–329, 1984

    Google Scholar 

  27. Santen RJ: Aromatase inhibitors for treatment of breast cancer: Current concepts and new perspectives. Breast Cancer Res Treat 7S:23–26, 1986

    Google Scholar 

  28. Miller WR: Aromatase inhibitors in the treatment of advanced breast cancer. Cancer Treat Rev 16:83–93, 1989

    Google Scholar 

  29. Cocconi G, Bisagni G, Ceci G, Bacchi M, Boni C, Brugia M, Carpi A, Did Costanzo F, Franciosi V, Gori S, Indelli M, Passalacqua R: Low-dose aminoglutethimide with or without hydrocortisone replacement as a first-line endocrine treatment in advanced breast cancer: A prospective randomized trial of the Italian Oncology Group for Clinical Research. J Clin Oncol 10:984–989, 1991

    Google Scholar 

  30. Lonning PE, Joannessen DC, Thorsen T: Alteration in the production rate and the metabolism of oestrone and oestrone sulphate in breast cancer patients treated with aminoglutethimide. Eur J Cancer 60:107–111, 1989

    Google Scholar 

  31. Lipton A, Santner SJ, Santen RJ, Harvey HA, Feil PD, White-Hershey D, Bartholomew MJ, Antle CE: Aromatase activity in primary and metastatic human breast cancer. Cancer 59:779–782, 1977

    Google Scholar 

  32. Bolufer P, Ricart E, Lluch A, Vazquez C, Rodriguez A, Ruiz A, Llopis F, Garcia-Conde J, Romero R: Aromatase activity and estradiol in human breast cancer: Its relationship to estradiol and epidermal growth factor receptors and to tumor-node-metastasis staging. J Clin Oncol 10:438–446, 1991

    Google Scholar 

  33. Miller WR, Hawkins RA, Forrest APM: Significance of aromatase activity in human breast cancer. Cancer Res 42 (Suppl):3365s-3368s, 1982

    Google Scholar 

  34. Harvey HA, Santen RJ, Osterman J, Samojlik E, White DS, Lipton A: A comparative trial of transsphenoidal hypophysectomy and estrogen suppression with aminoglutethimide in advanced breast cancer. Cancer 43: 2207–2214, 1979

    Google Scholar 

  35. Santen RJ, Worgul TJ, Samojlik E, Interrante A, Boucher AE, Lipton A, Harvey HA, White DS, Smart E, Cox C, Wells SA: A randomized trial comparing surgical adrenalectomy with aminoglutethimide plus hydrocortisone in women with advanced breast cancer. N Engl J Med 305:545–351, 1981

    Google Scholar 

  36. Lipton A, Harvey HA, Santen RJ, Boucher A, White D, Bernath A, Dixon R, Richards G, Shafik A: A randomized trial of aminoglutethimide versus tamoxifen in metastatic breast cancer. Cancer 50:2265–2268, 1982

    Google Scholar 

  37. Smith IE, Harris AL, Morgan M, Ford HT, Gazet JC, Harmer CL, White H, Parsons CA, Villardo A, Walsh G, McKinna JA: Tamoxifen versus aminoglutethimide in advanced breast carcinoma: A randomized cross-over trial. Brit Med J 283:1432–1434, 1981

    Google Scholar 

  38. Alonso-Munoz MC, Ojeda-Gonzalez MB, Beltran-Fabregat M, Dorca-Ribugent J, Lopez-Lopez L, Borras-Balada J, Cardenal-Alemany F, Gomez-Batiste Y, Fabregat-Mayol J, Viladiu-Quemada P: Randomized trial of tamoxifen versus aminoglutethimide and versus combined tamoxifen and aminoglutethimide in advanced postmenopausal breast cancer. Oncology 45:350–353, 1988

    Google Scholar 

  39. Gale K, Gelman R, Tormey D, Cummings F, for the Eastern Cooperative Oncology Group: Hormonotherapy for metastatic breast cancer. Proc ASCO 2:105, 1983

    Google Scholar 

  40. Ragaz J, Ibrahim E, Lehay M, Spinelli J: Aminoglutethimide (AG) and tamoxifen (T) in combination, versus AG, versus T in metastatic breast cancer — 6 years update. Proc ASCO 3:119, 1984

    Google Scholar 

  41. Santen RJ, Worgul TJ, Lipton A, Harvey H, Boucher A, Samojlik E, Wells SA: Aminoglutethimide as treatment of postmenopausal women with advanced breast carcinoma. Ann Int Med 96:94–101, 1982

    Google Scholar 

  42. Ceci G, Passalacqua R, Bisagni G, Bella M, Cocconi G: Aminoglutethimide in advanced breast cancer. Tumori 71:483–489, 1985

    Google Scholar 

  43. Budzar AU, Powell KC, Legha SS, Blumenschein GR: Treatment of advanced breast cancer with aminoglutethimide after therapy with tamoxifen. Cancer 50: 1708–1712, 1982

    Google Scholar 

  44. Kaye SB: Results obtained with aminoglutethimide in tamoxifen-resistant patients.In: Paesi FJA (ed) Aminoglutethimide (Orimeten). Mechanism of Action and Clinical Results in Breast Cancer. Ciba-Geigy, Basel, 1982, pp 171–180

    Google Scholar 

  45. Kvinnsland S, Dahl O: Aminoglutethimide treatment in advanced breast cancer: An efficient therapy as a late endocrine alternative in a sequential therapeutic approach. Breast Cancer Res Treat 3:73–76, 1983

    Google Scholar 

  46. Canney PA, Priestman TJ, Griffiths T, Latief TN, Mould JJ, Spooner D: Randomized trial comparing aminoglutethimide with high-dose medroxyprogesterone acetate in the therapy for advanced breast carcinoma. J Natl Cancer Inst 80:1147–1151, 1988

    Google Scholar 

  47. Nemoto T, Rosner D, Patel JK, Dao TL: Aminoglutethimide in patients with metastatic breast cancer. Cancer 63:1673–1675, 1989

    Google Scholar 

  48. Brufman G, Biran S: Second line hormonal therapy with aminoglutethimide in metastatic breast cancer. Acta Oncol 29:717–720, 1990

    Google Scholar 

  49. Garcia-Giralt E, Ayme Y, Carcon M, Daban A, Delozier T, Fargeot P, Fumoleau P, Gorins A, Guerin D, Guerin R, Maillart P, Mauriac L, May-Levin F, Metz R, Namer M, Olivier JP, Pommatau E, Pouillard P, Pujade-Lauraine E, Rouesse J, Serrou B, Vitse M, Zylberait D: Second and third line hormonal therapy in advanced postmenopausal breast cancer: A multicenter randomized trial comparing medroxyprogesterone acetate with aminoglutethimide in patients who have become resistant to tamoxifen. Breast Cancer Res Treat 24:139–145, 1992

    Google Scholar 

  50. Lundgren S, Gundersen S, Klepp R, Lonning PE, Lund E, Kvinnsland S: Megestrol acetate versus aminoglutethimide for metastatic breast cancer. Breast Cancer Res Treat 14:201–206, 1989

    Google Scholar 

  51. Congdon J, Green S, O'Sullivan J, Hynes H, Belt R, Gail K, Zidar B, Osborne CK: Megestrol acetate and aminoglutethimide/hydrocortisone in sequence or in combination as second-line endocrine therapy of estrogen receptor positive metastatic breast cancer. Proc ASCO 10:43, 1991

    Google Scholar 

  52. James PPB, Williams CJ: Phase III trial of trilostane vs aminoglutethimide in metastatic postmenopausal breast cancer. Proc ASCO 11:49, 1992

    Google Scholar 

  53. Chakraborty J, Hopkins R, Parke DV: Inhibition studies in the aromatization of androstenedione by human placental microsome preparations. Biochem J 130:19P-20P, 1972

    Google Scholar 

  54. Santen RJ, Santner S, Davis B, Veldhuis J, Samojlik E, Ruby E: Aminoglutethimide inhibits extraglandular estrogen production in postmenopausal women with breast carcinoma. J Clin Endocrinol Metab 47:1257–1265, 1978

    Google Scholar 

  55. Santen RJ, Lipton A, Harvey H, Boucher AE, Henderson C: Pharmacologic mechanisms of oestrogen suppression with aminoglutethimide in women with breast cancer.In: Nagel FA, Santen RJ (eds) Aminoglutethimide as an Aromatase Inhibitor in the Treatment of Cancer. Hans Huber Publ., Berne, 1984, pp 38–57.

    Google Scholar 

  56. Stuart-Harris R, Dowsett M, D'Souza A, Donaldson A, Harris AL, Jeffcoate SL, Smith IE: Endocrine effects of low dose aminoglutethimide as an aromatase inhibitor in the treatment of breast cancer. Clin Endocrinol 22:219–226, 1985

    Google Scholar 

  57. Dowsett M, Jeffcoate SL, Santner S, Santen RJ, Stuart-Harris R, Smith DE: Low dose aminoglutethimide and aromatase inhibitors. Lancet i:175–176, 1985

    Google Scholar 

  58. Samojlik E, Santen RJ: Adrenal suppression with aminoglutethimide. III. Comparison of plasma Δ4-and Δ5- steroids in postmenopausal women treated for breast carcinoma. J Clin Endocrinol Metab 47:717–729, 1978

    Google Scholar 

  59. Badder EM, Lerman S, Santen RJ: Aminoglutethimide stimulates extra-adrenal Δ4-androstenedione production. J Surg Res 34:380–383, 1983

    Google Scholar 

  60. Dowsett M, Harris AL, Stuart-Harris R, Hill M, Cantwell BMJ, Smith IE, Jeffcoate SL: A comparison of the endocrine effects of low dose aminoglutethimide with and without hydrocortisone in postmenopausal breast cancer patients. Br J Cancer 52:525–529, 1985

    Google Scholar 

  61. Franciosi V, Cocconi G, Bozzetti C, Bacchi M, Ceci G: Endocrine effects of low dose aminoglutethimide (AG) plus hydrocortisone compared with those of low dose AG alone in postmenopausal advanced breast cancer. Proc 4th EORTC Breast Cancer Working Conference, London, Abstract F 1–12, July 1987

    Google Scholar 

  62. Harris AL, Dowsett M, Smith IE, Jeffcoate S: Hydrocortisone alone vs hydrocortisone plus aminoglutethimide: A comparison of the endocrine effects in postmenopausal breast cancer. Eur J Cancer Clin Oncol 20:463–469, 1984

    Google Scholar 

  63. Harris AL, Cantwell BMJ, Carmichael J, Dawes P, Robinson A, Farndon J, Wilson R: Phase II study of low dose aminoglutethimide 250 mg/day plus hydrocortisone in advanced postmenopausal breast cancer. Eur J Cancer Clin Oncol 25:1105–1111, 1989

    Google Scholar 

  64. Bonneterre J, Pion JM, DeMaille A: Aminoglutethimide a faible dose (500 mg/jour) et hydrocortisone (30 mg/jour) dans le cancer evolué du sein. Bull Cancer 74:241–247, 1987

    Google Scholar 

  65. Crivellari D, Galligioni E, Frustaci S, Gasparini G, Vaccher E, Lo-Re G, Talamini R, Monfardini S, Ambrosio G: Low-dose aminoglutethimide plus steroid replacement in advanced breast cancer patients resistant to conventional therapy. Cancer Invest 7:113–116, 1989

    Google Scholar 

  66. Stuart-Harris R, Dowsett M, Bozek T, McKinna JA, Gazet JC, Jeffcoate SL, Kurkure A, Carr L, Smith IE: Low-dose aminoglutethimide in treatment of advanced breast cancer. Lancet ii:604–606, 1984

    Google Scholar 

  67. Murray R, Pitt P: Low-dose aminoglutethimide without steroid replacement in the treatment of postmenopausal women with advanced breast cancer. Eur J Cancer Clin Oncol 21:19–22, 1985

    Google Scholar 

  68. Hoeffken K, Miller AA, Miller B, Becher R, Aulbert E, Hoffman B, Anders CU, Callies R, Schmidt CG: Niedrigdosierte Aminoglutethimide-Therapie ohne Cortisolsubstitution bein metastatisierenden Mammakarzinom in der Postmenopause. Med Klin 81:638–642, 1986

    Google Scholar 

  69. Bruning PF, Bonfrer JMG, Hart AAM, Van Der Linden E, De Jong-Bakker M, Moolenaar AJH, Nooijen WJ: Low dose aminoglutethimide without hydrocortisone for the treatment of advanced postmenopausal breast cancer. Eur J Cancer Clin Oncol 25:369–376, 1989

    Google Scholar 

  70. Willard EM, Carpenter JT: Low dose aminoglutethimide is active in metastatic breast cancer. Proc ASCO 10:55, 1991

    Google Scholar 

  71. Hoeffken K, Kempf H, Miller AA, Miller B, Schimdt CG, Faber P, Kley HK: Aminoglutethimide without hydrocortisone in the treatment of postmenopausal patients with advanced breast cancer. Cancer Treat Rep 70:1153–1157, 1986

    Google Scholar 

  72. Santen RJ, Wells SA, Cohn N, Demers LM, Misbin RI, Foltz EL: Compensatory increase in TSH secretion without effect on prolactin secretion in patients treated with aminoglutethimide. J Clin Endocrinol Metab 45: 739–746, 1977

    Google Scholar 

  73. Murray RML, Pitt P: Treatment of advanced metastatic breast cancer, carcinoma of the prostate and endometrial cancer with aminoglutethimide.In: Nagel GA, Santen RJ (eds) Aminoglutethimide as an Aromatase Inhibitor in the Treatment of Cancer. Hans Huber Publ., Berne, 1984, pp 109–122

    Google Scholar 

  74. Kissin MW, Kark AE: Irreversible thrombocytopenia following aminoglutethimide. Cancer Treat Rep 67: 849, 1983

    Google Scholar 

  75. Rodman DM, Hanley M, Parsons P: Aminoglutethimide, alveolar damage, and hemorrhage (letter). Ann Int Med 105:633, 1986

    Google Scholar 

  76. Perrault DJ, Domovitch E: Aminoglutethimide and cholestasis (letter). Ann Int Med 100:160, 1984

    Google Scholar 

  77. McCraken M, Benson EA, Hickling P: Systemic lupus erythematosus induced by aminoglutethimide. Br Med J 281:1254, 1980

    Google Scholar 

  78. Bonneterre J, Nguyen M, Hecquet B, Fournier Ch, DeMaille A: Dyslipémie induite par l'aminoglutethimide. Etude clinique. Bull Cancer 72:99–103, 1985

    Google Scholar 

  79. Ceci G, Passalacqua R, Bisagni G, Bella M, Cocconi G: Aminoglutethimide and serum cholesterol. Lancet ii:358, 1985

    Google Scholar 

  80. Lonning PE, Kvinnsland S, Jahren G: Aminoglutethimide and warfarin. A new important drug interaction. Cancer Chemother Pharmacol 12:10–12, 1984

    Google Scholar 

  81. Ingle JN, Green SJ, Ahmann DL, Long HJ, Edmonson JH, Rubin J, Chang MN, Creagan ET: Randomized trial of tamoxifen alone or combined with aminoglutethimide and hydrocortisone in women with metastatic breast cancer. J Clin Oncol 4:958–964, 1986

    Google Scholar 

  82. Milsted R, Habeshaw T, Kayes S, Sangster G, Macbeth F, Campbell-Ferguson J, Smith D, Calman K: A randomized trial of tamoxifen versus tamoxifen with aminoglutethimide in postmenopausal women with advanced breast cancer. Cancer Chemother Pharmacol 14:272–273, 1985

    Google Scholar 

  83. Wander HE, Nagel GA, Blossey HC, Kleeberg U: Aminoglutethimide and medroxyprogesterone acetate in the treatment of patients with advanced breast cancer. A phase II study of the Association of Medical Oncology of the German Cancer Society (AIO). Cancer 58: 1985–1989, 1986

    Google Scholar 

  84. Horton J, Knuiman M, Keller AM, Vogel H, Gale KE, Hahn RG, Rosenbluth RJ, Tormey DC: Combination hormone therapy for metastatic breast cancer. An ECOG study of megestrol and aminoglutethimide. Cancer 60:2137–2140, 1987

    Google Scholar 

  85. Gennatas CS, Kalovidouris A, Paraskeuas EA, Kouvaris J, Trichopoulos D, Papavasiliou C: A randomized phase II trial of aminoglutethimide and hydrocortisone versus combined aminoglutethimide, hydrocortisone and fluoxymesterone in advanced breast cancer. Radiother Oncol 9:217–220, 1987

    Google Scholar 

  86. Powles TJ, Ashley S, Ford HT, Gazet JC, Nash AG, Neville AM, Coombes RC: Treatment of disseminated breast cancer with tamoxifen, aminoglutethimide, hydrocortisone and danazol, used in combination or sequentially. Lancet i:1369–1372, 1984

    Google Scholar 

  87. Hardy JR, Powles TJ, Judson IR, Sinnett HD, Ashley SE, Coombes RC, Ellin CL: Combination of tamoxifen, aminoglutethimide, danazol and medroxyprogesterone acetate in advanced breast cancer. Eur J Cancer Clin Oncol 26:824–827, 1990

    Google Scholar 

  88. Santen RJ, Samojlik E, Wells SA: Resistance of the ovary to blockade of aromatization with aminoglutethimide. J Clin Endocrinol Metab 51:473–477, 1980

    Google Scholar 

  89. Harris AL, Dowsett M, Jeffcoate SL, McKinna JA, Morgan M: Endocrine and therapeutic effects of aminoglutethimide in premenopausal patients with breast cancer. J Clin Endocrinol Metab 55:718–722, 1982

    Google Scholar 

  90. Wander HE, Blossey HCh, Nagel GA: Aminoglutethimide in the treatment of premenopausal patients with metastatic breast cancer. Eur J Cancer Clin Oncol 22: 1371–1374, 1986

    Google Scholar 

  91. Lipton A, Santen RJ, Harvey HA, Manni A, Simmonds MA, White-Hershey D, Bartholomew MJ, Walker BK, Dixon RH, Valdevia DE, Gordon RA: A randomized trial of aminoglutethimide ± estrogen before chemotherapy in advanced breast cancer. Am J Clin Oncol 10:65–70, 1987

    Google Scholar 

  92. Grem JL, Falkson G, Love RR, Tormey DC: A phase II evaluation of combination chemotherapy plus aminoglutethimide in women with metastatic or recurrent breast carcinoma. An Eastern Cooperative Oncology Group pilot study. Am J Clin Oncol 11: 528–534, 1988

    Google Scholar 

  93. Fernandez O, Morera F, Cervellino JC, Gomes Benavides N, Jouti SF, Pirisi C, Pannuzio O, Sanchez O, Bordenave R: Treatment of advanced breast cancer with CMF + aminoglutethimide and hydrocortisone acetate. Proc ASCO 28:230, 1987

    Google Scholar 

  94. Tormey DC, Falkson HC, Falkson G, Voelkel J, Crowley J, Davis TE: Dibromodulcitol and adriamycin ± tamoxifen in advanced breast cancer. Am J Clin Oncol 5:33–39, 1982

    Google Scholar 

  95. Cocconi G, De Lisi V, Boni C, Mopri P, Malacarne P, Amadori D, Giovanelli E: Chemotherapy versus combination of chemotherapy and endocrine therapy in advanced breast cancer. A prospective randomized study. Cancer 51:581–588, 1983

    Google Scholar 

  96. Mouridsen HT, Rose C, Engelsman E, Sylvester R, Rotmensz N: Combined cytotoxic and endocrine therapy in postmenopausal patients with advanced breast cancer. A randomized study of CMF vs CMF plus tamoxifen. Eur J Cancer Clin Oncol 21:291–299, 1985

    Google Scholar 

  97. Early Breast Cancer Trialists Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 339:1–15, 71–85, 1992

    Google Scholar 

  98. Jones AL, Powles TJ, Law M, Tidy A, Easton D, Coombes RC, Smith IE, McKinna JA, Nash A, Ford HT, Gazet JL: Adjuvant aminoglutethimide for postmenopausal patients with primary breast cancer: Analysis at 8 years. J Clin Oncol 10:1547–1552, 1992

    Google Scholar 

  99. Goldenberg IS: Clinical trial of Δ1-testololactone (NSC 23759), medroxyprogesterone acetate (NSC 26386), and oxylone acetate (NSC 47438) in advanced female mammary cancer. A report of the Cooperative Breast Cancer Group. Cancer 23:109–112, 1969

    Google Scholar 

  100. Fried HJ, Thoma RW, Klingsberg A: Oxidation of steroids by microorganisms. III. Side chain degradation, ring D-cleavage and dehydrogenation in ring A [communication]. J Am Chem Soc 75:5764–5765, 1953

    Google Scholar 

  101. Segaloff A, Weeth JB, Meyer KK, Rongone EL, Cunningham MEG: Hormonal therapy in cancer of the breast. XIX. Effect of oral administration of Δ1-testololactone on clinical course and hormonal excretion. Cancer 15:633–635, 1962

    Google Scholar 

  102. Van Rymenant M, Coune A, Tagnon HJ, Somon S: Le traitement hormonal du cancer du sein en phase avancée. Methodes d'études - comparaison de la delta-1-testololactone avec le propionate de testosterone. Acta Clin Belg 18:469–479, 1963

    Google Scholar 

  103. Cantino TJ, Gordan GS: High-dosage Δ1-testololactone therapy of disseminated carcinoma of the breast. Cancer 20:458–461, 1967

    Google Scholar 

  104. Goldenberg IS, Waters MN, Ravdin RS, Ansfield FJ, Segaloff A: Androgenic therapy for advanced breast cancer in women. A report of the Cooperative Breast Cancer Group. J Am Med Assoc 223:1267–1268, 1973

    Google Scholar 

  105. Volk H, Deupree RH, Goldenberg IS, Wilde RC, Carabasi RA, Escher GC: A dose response evaluation of delta-1-testololactone in advanced breast cancer. Cancer 33:9–13, 1974

    Google Scholar 

  106. Siiteri PK, Thompson EA: Studies of human placental aromatase. J Steroid Biochem 6:317–320, 1975

    Google Scholar 

  107. Barone RM, Shamonki IM, Siiteri PK, Judd HL: Inhibition of peripheral aromatization of androstenedione to estrone in postmenopausal women with breast cancer using Δ1-testololactone. J Clin Endocrinol Metab 49:672–676, 1979

    Google Scholar 

  108. Dao TL: Estrogen synthesis in human breast tumor and its inhibition by testololactone and bromoandrostenedione. Cancer Res 43:3338s-3341s, 1982

    Google Scholar 

  109. Brodie AMH, Garrett WM, Hendrickson JR, Marcotte PA, Robinson CH: Inactivation of aromatase activity in placental and ovarian microsomes by 4-hydroxyandrostene-3,17-dione and 4-acetoxyandrostene-3,17-dione. Steroids 38:693–702, 1981

    Google Scholar 

  110. Vigersky RA, Mozingo D, Eil C, Purohit V, Bruton J: The antiandrogenic effects of Δ1-testololactone (Teslac)in vivo in rats andin vitro in human cultured fibroblasts, rat mammary carcinoma cells, and rat prostate cytosol. Endocrinol 110:214–219, 1982

    Google Scholar 

  111. Kaufman RJ: Advanced breast cancer. Additive hormonal therapy. Cancer 47:2398–2403, 1981

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medical Oncology Division, University Hospital, Parma, Italy

    Giorgio Cocconi M.D.

Authors
  1. Giorgio Cocconi M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cocconi, G. First generation aromatase inhibitors — aminoglutethimide and testololactone. Breast Cancer Res Tr 30, 57–80 (1994). https://doi.org/10.1007/BF00682741

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00682741

Key words

Search

Navigation